Pulmonary Lymphangioleiomyomatosis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for pulmonary lymphangioleiomyomatosis. 7 active patents protecting 1 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
7
Active US patents
58/100
Avg vulnerability
—
Annual revenue covered

Originators in Pulmonary Lymphangioleiomyomatosis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer 7 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating pulmonary lymphangioleiomyomatosis. Each bar = one year. Y-axis scaled to peak year (4 patents).

1
29
1
30
4
36
1
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Rapamune
sirolimus
 Pfizer 7 58 — 2029-02-14

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8911786 Rapamune method of use 75 2029-02-14
12133844 Rapamune method of use 75 2036-06-29
10973806 Rapamune method of use 62 2036-06-29
12061183 Rapamune formulation 55 2036-03-05
11497737 Rapamune formulation 50 2040-10-28
10206887 Rapamune formulation 48 2030-04-15
10705070 Rapamune formulation 42 2036-03-05

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10705070 Rapamune formulation 42 2036-03-05
10206887 Rapamune formulation 48 2030-04-15
11497737 Rapamune formulation 50 2040-10-28
12061183 Rapamune formulation 55 2036-03-05
10973806 Rapamune method of use 62 2036-06-29
12133844 Rapamune method of use 75 2036-06-29
8911786 Rapamune method of use 75 2029-02-14

Related